Moxee

#StartupSpotlight - Biomatter Biomatter is a SynBio company that creates new proteins and enzymes using their Intelligent Architecture platform. They want to change health and sustainable manufacturing by making proteins with unique functions and properties. 📖 Biomatter.ai started in 2018 in Vilnius, Lithuania. 📖 They were created to solve the problems with old methods of protein engineering, which are slow, expensive, and not very accurate. 📖 By using AI and computer tools, Biomatter.ai speeds up the process and opens new possibilities for engineered proteins in healthcare and manufacturing. 𝗣𝗿𝗼𝗯𝗹𝗲𝗺 𝗦𝗼𝗹𝘃𝗲𝗱: Efficiency: Old methods are slow and use a lot of resources. Precision: Their platform makes designing proteins more accurate, allowing for specific and new functions hard to achieve with traditional methods. Scalability: The platform can handle huge amounts of protein data, making it useful for large-scale projects in healthcare, sustainability, and industry. 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲𝘀: 2019: Published a study showing their AI tool can analyze large enzyme datasets and design new enzymes. 2021: Raised €500,000 in seed funding to improve their AI-driven protein design technology. 2023: Partnered with ArcticZymes Technologies ASA to create new enzyme-based products using their platform. 2024: Secured €6.5 million in funding to expand their protein design capabilities. Achievements in 2024 Check 'em out! 👏

The first CRISPR medicine was approved yesterday. 😲 ... And, it's in the UK!! The decision could transform the treatment of sickle-cell disease. This is the first medicine based on CRISPR technology that has been approved... ANYWHERE!! (Perhaps the only benefit of Brexit 🤣) Link in the comments!

Last week was HUGE for funding! 💸 👏 Here's the biotech round-up: [1] Genezen - Cell Therapy, Indiana - $18,500,000 (Venture Round) [2] Stellaromics Inc. - Multi-Omics, Massachusetts - $25,000,000 (Series A) [3] Progenx - Neuroscience, New York - $15,000,000 (Series A) [4] GENOME INSIGHT INC. - Multi-Omics, New York - $23,000,000 (Series A) [5] Gate Bioscience - Protein Degradation, California - $60,000,000 (Series A) [6] Siren Biotechnology - AAV immuno-gene therapy, California - $4,000,000 (Grant) [7] Lucid Diagnostics - Cancer Dx, New York - $5,000,000 (Venture Round) [8] Aqtual, Inc. - Precision Medicine, California - $16,000,000 (Series A) [9] Engine Biosciences - Biomarker Discovery, California - $27,000,000 (Series A) [10] Annovis Bio, Inc. - Alzheimer’s and Parkinson’s, Pennsylvania - $7,500,000 (Post) [11] Annovis Bio, Inc. - Alzheimer’s and Parkinson’s, Pennsylvania - $7,500,000 (Post) [12] 100X Bioassay - T-Cell Research, Massachusetts - $40,000 (Pre-seed) [13] BRAINBox Solutions, Inc. - mTBI, Diagnosis & Prognosis, Virginia - (Series B) [14] Granata Bio - Fertility Solutions , Massachusetts - $96,667 (Seed Round) [15] MapLight Therapeutics, Inc. - Therapeutics for CNS disorders, California - $225,000,000, (Series C) #biotech #funding

London-based Automata, a biotech focusing on robotic automation for life sciences labs, has raised $40 million in funding. 👏 🤑 👏 🤑 This follows a $50 million Series B round in January 2022. Investors include Dimension and A.P. Moller Holding, along with existing investors. Automata has experienced significant growth with a 150% revenue increase and a 12-fold rise in live system hours. Their LINQ automation platform offers adaptability for labs in various sectors, helping streamline processes and enhance efficiency in the face of changing scientific demands.

Adela, Inc. - a pioneer in blood testing for MRD monitoring and early cancer detection has secured $48 million in financing. 👏 This funding round involves existing investors like F-Prime Capital, OrbiMed, Deerfield Management, Decheng Capital, and RA Capital Management, as well as new investor... Labcorp! These funds will support the advancement of Adela's tech platform, including their MRD monitoring product. They also plan to develop a multi-cancer early detection product based on the same platform. Lisa Alderson, an accomplished healthcare leader, has been appointed as Adela's interim CEO. #biotech #funding #MoxeeMolecular

Fed up with the lack of Bioinformatics opportunities in Massachusetts? Lacking the opportunity to utilise your commercial acumen? Unable to manage independent projects? Frustrated with PhD's as a non-negotiable? Bioinformatician of any seniority, with experience in Mass Spec or Proteomic data sets? Send an email to [email protected] for a link to our Calendar. 👇